Improvements in gene therapy: Averting the immune response to adenoviral vectors

BioDrugs

Volumn 16, Issue 1, 2002, Pages 3-10

  Ritter, T ^a   Lehmann, M ^b   Volk, H ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ADENOVIRUS VECTOR; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; CYTOKINE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GENOMIC DNA; IMMUNOSUPPRESSIVE AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; T LYMPHOCYTE RECEPTOR; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ANIMAL MODEL; CYSTIC FIBROSIS; DNA VIRUS; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; GRAFT REJECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RAT; REVIEW; T LYMPHOCYTE ACTIVATION; TARGET CELL; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS GENOME; VIRUS PARTICLE; VIRUS RECOMBINANT;

EID: 0036222982     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200216010-00001     Document Type: Review

References (94)

1. Adenovirus vectors for high-efficiency gene transfer into mammalian cells
2. Adenoviruses
3. In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human serum albumin from recombinant human adenoviruses
4. Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors
5. Characteristics of a human cell line transformed by DNA from human adenovirus type 5
6. Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors
7. Gene therapy - Promises, problems and prospects
8. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics
9. Cell receptors involved in adenovirus entry
10. Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors
11. Gene transfer by adenovectors
12. Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses
13. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo
14. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration
15. Blood clearance rates of adenovirus type 5 in mice
16. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ
17. Intravenous administration of recombinant adenoviruses causes thrombocytopenia, anemia and erythroblastosis in rabbits
18. Worldwide epidemiology of human adenovirus infections
19. Immune responses to adenovirus and adeno-associated virus in humans
20. Immunologic aspects of renal disease
21. Renal manifestations of hepatitis C infection
22. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen
23. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
24. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo
25. Immunologic barriers to hepatic adenoviral gene therapy for transplantation
26. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver
27. Rapid clearance of syngeneic transplanted hepatocytes following transduction with E-1-deleted adenovirus indicates early host immune responses and offers novel ways for studying viral vector, target cell and host interactions
28. Immune response to recombinant adenovirus in humans: Capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes
29. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo
30. Promoter attenuation in gene therapy: Interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression
31. Stimulatory and inhibitory action of cytokines on the regulation of hCMV-IE promoter activity in human endothelial cells
32. Human gene marker/therapy clinical protocols
33. Gene therapy for cystic fibrosis
34. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
35. Recombinant adenovirus gene transfer in adults with partial ornithine transcarbamylase deficiency (OTCD)
36. Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells
37. Tolerogenic antibodies and fusion proteins to prevent graft rejection and treat autoimmunity
38. How do monoclonal antibodies induce tolerance? A role for infectious tolerance?
39. Nondepleting anti-CD4 antibody treatment prolongs lung-directed E1-deleted adenovirus-mediated gene expression in rats
40. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors
41. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver
42. Gene therapy with recombinant adenovirus vectors: Evaluation of the host immune response
43. Immune response after adenoviral gene transfer in syngeneic heart transplants: Effects of anti-CD4 monoclonal antibody therapy
44. Immunomodulation and adenoviral gene transfer to the lungs of nonhuman primates
45. Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse
46. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA41g administration
47. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung
48. Immunosuppression prolongs adenoviral mediated transgene expression in cardiac allograft transplantation
49. Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat
50. Transient immunosuppression with 15-deoxyspergualin prolongs reporter gene expression and reduces humoral immune response after adenoviral gene transfer
51. Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles
52. Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver
53. Inhibition of tumor necrosis factor alpha by an adenovirus-encoded soluble fusion protein extends transgene expression in the liver and lung
54. Ischemia/reperfusion injury-mediated down-regulation of adenovirus-mediated gene expression in a rat heart transplantation model is inhibited by co-application of a TNFRp55-Ig chimeric construct
55. Oral tolerance: Mechanisms and therapeutic applications
56. Neonatal tolerant immunity for vaccination against autoimmunity
57. The thymus and central tolerance
58. Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long-term gene therapy in Gunn rats
59. Gene transfer to the thymus. A means of abrogating the immune response to recombinant adenovirus
60. Long term correction of bilirubin-UDP-glucuronosyhltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period
61. Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors
62. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses
63. Circumventing the immune response to adenovirus-mediated gene therapy
64. 'Sero-switch' adenovirus-mediated in vivo gene transfer: Circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype
65. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype
66. Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: Implications in gene therapy
67. Pseudopackaging of adenovirus type 5 genomes into capsids containing the hexon proteins of adenovirus serotypes B, D, or E
68. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F
69. One step ahead of the game: Viral immunomodulatory molecules
70. Viruses use stealth technology to escape from the host immune system
71. The constitutive expression of the immunomodulatory gp19k protein in E1-, E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector
72. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression
73. Heterologous expression of adenovirus E3-gpl9K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo
74. Interactions between the immune system and gene therapy vectors: Bidirectional regulation of response and expression
75. Inflammation-induced recombinant protein expression in vivo using promoters from acute-phase protein genes
76. Physiologically responsive gene therapy
77. Considerations and challenges for the achievement of targeted gene delivery
78. Genetic targeting of adenoviral vectors
79. Targeting adenovirus
80. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types
81. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism
82. Recombinant adenovirus vectors with knobless fibers for targeted gene transfer
83. Recombinant human adenovirus: Targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium
84. Targeted adenovirus-mediated gene delivery to T cells via CD3
85. Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery
86. Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: Requirement for E4 ORF3
87. Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3
88. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector
89. A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal
90. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
91. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity
92. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons
93. Expanded-capacity adenoviral vectors - The helper-dependent vectors